

# CANCER CARE

## EXPERT PROFESSIONAL PRACTICE CURRICULUM

Professional curriculum to support members with  
the knowledge, skills, experience and behaviours  
to advance in their practice

2014

ROYAL PHARMACEUTICAL SOCIETY  
**FACULTY**

## Disclaimer

This publication is intended as a guide and may not always include all information relating to its subject matter.

You should interpret all information and advice in light of your own professional knowledge and all relevant pharmacy and healthcare literature and guidelines.

Nothing in this publication constitutes legal advice and cannot be relied upon as such.

Whilst care has been taken to ensure the accuracy of content RPSGB excludes to the fullest extent permissible by law any liability whether in contract, tort or otherwise arising from your reliance on any information or advice.

This curriculum has been produced by RPS Faculty partners to support continued advancement in all areas of pharmacy practice.

During 2014 the Curricula Panel of the RPS Faculty will continue to develop the vision for post graduate development to produce the highest quality pharmacy workforce. The Faculty will continue to work with experts and specialist groups to form new guidance for professional advancement. The layout and themes in these curricula may be subject to change. Reviews of curricula can be expected annually while the Faculty is being set up. Please check that you are using the most up to date version of the curricula on the RPS Faculty website ([www.rpharms.com/faculty](http://www.rpharms.com/faculty)).

Endorsed by



# Acknowledgements

---

The mapping tables in this document use the Royal Pharmaceutical Society Advanced Pharmacy Framework (APF) which builds on the widely used Advanced to Consultant Level Framework (ACLF) which was developed by the Competency Development and Evaluation Group (CoDEG).

The template and content of this document was developed from the document “Adult Critical Care - Specialist Pharmacy Practice” (London: Department of Health; 2005) produced by the UKCPA Critical Care Pharmacists Group in collaboration with key department of health (DH) personnel and senior NHS pharmacists.

## Primary Contributors

- Specialist Curriculum Group Professional Development Programme.
- Specialist Curriculum Group Speciality Handbooks for Specialist and Advanced Practice for other Clinical Specialities.
- British Oncology Pharmacy Association (BOPA).
- Cancer Network Pharmacists.
- College of Pharmacy Practice, Faculty of Cancer Pharmacy.
- The United Kingdom Oncology Nursing Society (UKONS) Primary Contributors:
  - Maggie Crowe, Macmillan Development Manager, South West England. President UKONS 2009.
  - Richard Henry
  - Elaine Lennan
  - Michele Pengelly, Velindre Hospital, Wales
  - Helen Taylor, Chief Pharmacist, The Whittington Hospital NHS Trust
  - Kumud Kantilal, Macmillan Principal Network Pharmacist, Lead for Education and Training, Guy's and St Thomas' NHS Foundation Trust/South East London Cancer Network.
  - Nicola Stoner, Consultant Pharmacist Cancer Services, Oxford Radcliffe Hospitals NHS Trust.

## Reviewers

- Alison Innes, Advanced Pharmacy Practice Programme Director & Course Coordinator, School of Pharmacy, University of London.
- Steve Williamson, Consultant Pharmacist in Cancer Services, Northumbria Healthcare/North of England Cancer Network.
- Bruce Burnett, Pharmacy Department, North Wales Cancer Treatment Centre, Glan Clwyd Hospital.
- British Oncology Pharmacy Association (BOPA).
- College of Pharmacy Practice, Faculty of Cancer Pharmacy.
- The United Kingdom Oncology Nursing Society (UKONS).

# Professional Curriculum for Advanced Pharmacy Practice in Cancer Care

---

## Pharmaceutical Care of Cancer Patients

This curriculum provides an overview of the knowledge, skills, experiences and behaviours required to practice at advanced level in Cancer Care at three stages: Advanced Stage I, Advanced Stage II and Mastery, in line with the requirements of the APF.

The document is intended to be used by practitioners to support the development of their practice at an advanced level within Cancer Care. It encourages practitioners to think critically and to use knowledge in Cancer Care supporting informed decision making using knowledge from this and other related therapeutic areas to promote optimal medicines management for patients. The curriculum also encourages the development of skills in informed, critically relevant, effective discussion with other health and social care practitioners, peers and managers, where appropriate, to maximise optimal medicines related care for patients.

It is intended to be as useful to the wider community working within Cancer Care as possible from all sectors of care. The syllabus is not intended to cover every aspect of practice and inevitably overlaps with a number of specialities. Users are encouraged to link this syllabus with others in related fields, e.g. Palliative Care, Clinical Trials (also known as critical adjacencies).

This curriculum will be reviewed annually as to whether any update or changes are required. Every five years there will be an external review including external experts to re-evaluate the curriculum. Feedback is encouraged to ensure that the document is error-free, fit for purpose and accurately reflects the needs of pharmacists working at the specified stages.

# Knowledge, Skills, Experience and Behaviours

---

Practitioners will develop their portfolios linked to the APF ([www.rpharms.com](http://www.rpharms.com)). The recommended knowledge, skills, experience and behaviours which practitioners require to demonstrate competence at Advanced Stage I, Advanced Stage II and Mastery stage for the Expert Professional Practice and Collaborative Working Relationships clusters of the APF in an area of advanced practice, are listed here with additional notes and specific examples for working within Cancer Care. The APF mapping tables in this document link the recommended knowledge, skills, experience and behaviours with the relevant developmental descriptors. Examples of the recommended knowledge, skills, experience and behaviours are included below. For a comprehensive list see the mapping tables.

## Advanced Stage I

- Demonstrates basic competency in delivering cancer services to cancer patients through a record of reflective practice under the guidance of a more experienced oncology pharmacist.
- Basic ability to recognise problems and formulate treatment plans.
- Monitored ward visits/mentorship.
- Can perform case presentation.
- Can perform bedside case presentation.
- Ability to recommend justifiable courses of action.
- Demonstrate accurate reasoning.
- Recognises own limitations.
- Able to make decisions in a timely manner with limited information.
- Ability to prioritise problems.
- Demonstrates the ability to follow trust guidance related to the cancer wards and cytotoxic unit.
- Ability to persuade others about individual episodes of care.
- Demonstrates self motivation.
- Negotiates issues around an individual case.
- Communicates to cancer patients/next of kin in difficult settings.
- Demonstrates learning in difficult situations.
- Listens to patients, their next of kin, visitors and the multidisciplinary team (MDT).
- Member of BOPA and FCP or other local/national associations that provide appropriate level of clinical support.
- Presents to pharmacy and the multidisciplinary team (MDT).
- Communication is always clear, precise and appropriate.
- Works as part of the clinical pharmacy team.
- Recognises a situation outside competence and refers to supervising pharmacist (appropriate pharmaceutical problems are always appropriately referred).

## Advanced Stage II

- Carries out teaching regarding treatment of cancer patients to pharmacy, nursing, medical staff and other allied healthcare professionals (AHPs).
- Responsible for delivery of care of a wide range of cancers and called an oncology/haematology or cancer services pharmacist.
- Produces increasingly complex treatment plans.
- Demonstrates the ability to appraise information, make an informed decision with the evidence available and be able to justify/defend the decision to others.
- Develops policies and procedures specifically for the cytotoxic unit/chemotherapy day unit and or cancer ward.
- May be involved in the development of supplementary/independent prescribing in cancer.
- Ability to persuade or influence the cancer care team/pharmacy team with regard to complex cases, organisational change, research, guidelines and protocols.
- Motivates pharmacy clinical team (e.g. to follow a guideline, collect data).
- Negotiates issues between cancer care team and pharmacy such as prioritisation of chemotherapy supply and waiting times.
- Communicates to junior staff and multidisciplinary team colleagues.
- Is aware of communication skills and trained in communication with cancer patients.
- Participating Member of BOPA/FCP.
- Participates in local network, member of pharmacy/chemotherapy tumour board where appropriate.
- Presents to senior MDT including consultant level.
- Shares expertise with pharmacy and cancer care team.
- Recognition of expertise by the multidisciplinary team.
- Receives and effectively responds to requests for advice in specialist field from within the specialist area within the Trust, teaches junior staff to do so.
- Active participation in multi-disciplinary task forces/service developments.

# Resources for Curriculum Development

---

## Useful Websites

- NICE ([www.nice.org.uk/](http://www.nice.org.uk/))
- National Patient Safety Agency ([www.npsa.nhs.uk](http://www.npsa.nhs.uk))
- Department of Health ([www.dh.gov.uk](http://www.dh.gov.uk))
- BOPA Website ([www.bopawebsite.org](http://www.bopawebsite.org))
- BOPA Learning ([www.bopalearning.com](http://www.bopalearning.com))
- European Society of Oncology Pharmacy (<http://www.esop.li/>)
- National Institute for Health Research ([www.ncm.org.uk](http://www.ncm.org.uk))
- American Cancer Society ([www.cancer.org](http://www.cancer.org))
- American Society of Clinical Oncology ([www.asco.org](http://www.asco.org))
- Cancer Research UK ([www.cancerresearchuk.org](http://www.cancerresearchuk.org))
- Marie Curie Cancer Care ([www.mariecurie.org.uk](http://www.mariecurie.org.uk))
- MacMillan Cancer Support ([www.macmillan.org.uk](http://www.macmillan.org.uk))
- Learn Zone MacMillan (<http://learnzone.macmillan.org.uk/>)
- Palliative Drugs ([www.palliativedrugs.com](http://www.palliativedrugs.com))
- Memorial Sloan Kettering Cancer Care (<http://www.mskcc.org/cancer-care/integrative-medicine/about-herbs-botanicals-other-products>)
- International Society of Oncology Pharmacy Practitioners ([www.isopp.org](http://www.isopp.org))
- Haematology/Oncology Pharmacy Association ([www.hoparx.org](http://www.hoparx.org))
- Royal Pharmaceutical Society ([www.rpharms.com](http://www.rpharms.com))
- UKONS Oncology Nursing Society ([www.ukons.org](http://www.ukons.org))
- NHS England Chemotherapy Clinical Reference Group (<http://www.england.nhs.uk/npc-crg/group-b/b15>)

## Textbooks

- Clinical Oncology: Basic Principles and Practice, 4th Ed.  
Peter Hoskin, Anthony Neal  
Hodder Arnold, April 2009  
ISBN-10 0340972939  
ISBN-13 978-0340972939
- Cancer Management – A Multidisciplinary Approach 11th Ed.  
Editors Richard Pazdur, Lawrence D Wagman, Kevin A Camphausen  
Cmp United Business Media, May 2009  
ISBN-10 1891483625  
ISBN-13 978-1891483622
- The Royal Marsden Hospital Handbook of Cancer Chemotherapy  
David Brighton, Miriam Wood, Stephen R D Johnston, Hugo Ford  
Churchill Livingstone, Oct 2005  
ISBN-10 0443071012  
ISBN-13 978-0443071010
- Practical Chemotherapy  
Maxwell Summerhayes, Susanna Daniels  
Radcliffe Publishing Ltd, Dec 2003  
ISBN-10 1857759656  
ISBN-13 978-1857759655
- Palliative Care Formulary 4th Ed  
Robert Twycross, Andrew Wilcock  
palliativedrugs.com, Sep 2011  
ISBN 978-0-9552547-5-8

- The Cytotoxics Handbook 4th Ed  
Editor M.C. Allwood, Patricia Wright, Andrew Stanley  
Radcliffe Publishing Ltd, Dec 2002  
ISBN-10 1857755049  
ISBN-13 978-1857755046
- Oxford Handbook of Oncology 3rd Ed  
Editor Jim Cassidy, Donald Bissett, Roy Spence, Miranda Payne  
OUP Oxford, May 2010  
ISBN-10 0199563136  
ISBN-13 978-0199563135
- The Oral Anticancer Medicines Handbook  
Steve Williamson, Calum Polwart  
Lulu.com, Feb 2009  
ISBN-10 1409240444  
ISBN-13 978-1409240440
- The Syringe Driver: Continuous subcutaneous infusions in palliative care 2nd Ed  
Andrew Dickman, Jennifer Schneider, James Varga  
OUP Oxford, Mar 2005  
ISBN-10 019856693X  
ISBN-13 978-0198566939

## Examples of Journals to Refer to

- New England Journal of Medicine ([www.nejm.org](http://www.nejm.org))
- British Medical Journal ([www.bmj.com](http://www.bmj.com))
- The Lancet ([www.thelancet.com](http://www.thelancet.com))
- Clinical Pharmacist ([www.pjonline.com/clinical-pharmacist](http://www.pjonline.com/clinical-pharmacist)) and  
Pharmaceutical Journal (Cancer Series) ([www.pjonline.com](http://www.pjonline.com))
- Journal of Oncology Pharmacy Practice  
([www.rpharms.com/vx/exchange-sites/rps/946/ecurriculum/opp.sagepub.com](http://www.rpharms.com/vx/exchange-sites/rps/946/ecurriculum/opp.sagepub.com))
- American Journal of Hospital Pharmacy ([www.ajhp.org/content/33/2/129](http://www.ajhp.org/content/33/2/129))
- European Journal of Oncology Pharmacy  
([www.ppme.eu/Publications/EJOP/journal-information/About-EJOP](http://www.ppme.eu/Publications/EJOP/journal-information/About-EJOP))
- Journal of Clinical Oncology (<http://jco.ascopubs.org/>)

## National Guidance

- Improving Outcomes: a Strategy for Cancer, DOH 2011  
([www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_123371](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123371))
- The Cancer Drugs Fund, Guidance to Support Operation of the Cancer Drugs Fund in 2011-12, DOH 2011  
([www.dh.gov.uk/en/Consultations/Responsestoconsultations/DH\\_125683](http://www.dh.gov.uk/en/Consultations/Responsestoconsultations/DH_125683))
- The NHS Cancer Plan and the New NHS – Providing a Patient-Centred Service, DOH 2004  
([www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_4092531](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4092531))
- Manual of Cancer Services, DOH 2011 ([www.dh.gov.uk/en/Healthcare/Cancer/Treatment/DH\\_101998](http://www.dh.gov.uk/en/Healthcare/Cancer/Treatment/DH_101998))
- Cancer Reform Strategy, DOH Dec 2007  
([www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_081006](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081006))
- NICE Guidance - cancer service guidance, clinical guidelines & technology appraisals ([www.nice.org.uk](http://www.nice.org.uk))
- Calman-Hine Report  
([www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_4071083](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4071083))
- HSC2008/001 Updated National Guidance on the Safe Administration of Intrathecal Chemotherapy, DOH 2008  
([www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Healthservicecirculars/DH\\_086870](http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Healthservicecirculars/DH_086870))
- NPSA/2008/RRRR04. Vinca alkaloid minibags ([www.nrls.npsa.nhs.uk/resources/?EntryId45=59890](http://www.nrls.npsa.nhs.uk/resources/?EntryId45=59890))
- Chemotherapy services in England: ensuring quality and safety. A report from the National Chemotherapy Advisory Group (NCAG) August 2009  
([http://webarchive.nationalarchives.gov.uk/+www.dh.gov.uk/en/Consultations/Liveconsultations/DH\\_090150](http://webarchive.nationalarchives.gov.uk/+www.dh.gov.uk/en/Consultations/Liveconsultations/DH_090150))



- National Confidential Enquiry into Patient Outcomes and Death (NCEPOD) Report November 2008 ([www.ncepod.org.uk](http://www.ncepod.org.uk))
- NPSA-RRR 2008/001 Risks of Incorrect Dosing of Oral Anti-Cancer Medicines January 2008 ([www.nrls.npsa.nhs.uk/resources/?entryid45=59880](http://www.nrls.npsa.nhs.uk/resources/?entryid45=59880))
- BOPA Competency Framework for Specialist Oncology Pharmacists December 2004 ([www.bopawebsite.org/contentimages/publications/Competency\\_Framework.pdf](http://www.bopawebsite.org/contentimages/publications/Competency_Framework.pdf))
- CPPE Open Learning Pack – Cancer: in Relation to Pharmacy Practice September 2009 ([www.cppe.ac.uk/learning/Details.asp?TemplateID=CancerPP-D-01&Format=D&ID=21&EventID=39180](http://www.cppe.ac.uk/learning/Details.asp?TemplateID=CancerPP-D-01&Format=D&ID=21&EventID=39180))
- World Class Commissioning: Vision Department of Health, December 2007 ([www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_080956](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_080956))
- Improving Access to Medicines for NHS Patients A report for the Secretary of State for Health by Professor Mike Richards CBE. November 2008 ([www.dh.gov.uk/prod\\_consum\\_dh/groups/dh\\_digitalassets/@dh/@en/documents/digitalasset/dh\\_089952.pdf](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_089952.pdf))
- Guidance on NHS Patients who Wish to Pay for Additional Private Care Department of Health March 2009 ([www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_096428](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_096428))
- London Cancer New Drugs Group ([www.nelm.nhs.uk/en/Communities/NeLM/LCNDG/](http://www.nelm.nhs.uk/en/Communities/NeLM/LCNDG/))
- National Cancer Action Team ([www.ncat.nhs.uk](http://www.ncat.nhs.uk))

## Supporting References and External Resources

- BOPA Guidance for Non Medical Review and Prescribing of Anticancer Medicines and supportive therapies for Oncology and Haematology Patients June 2009. ([www.bopawebsite.org/contentimages/publications/Non\\_Medical\\_Prescribing\\_Review\\_Best\\_Practice\\_Guidelines\\_FINAL.pdf](http://www.bopawebsite.org/contentimages/publications/Non_Medical_Prescribing_Review_Best_Practice_Guidelines_FINAL.pdf))
- CEL 21 (2009) Safe Administration of Intrathecal cytotoxic Chemotherapy The Scottish Government Health Directorates, Healthcare Planning and Policy. ([www.sehd.scot.nhs.uk/mels/CEL2009\\_21.pdf](http://www.sehd.scot.nhs.uk/mels/CEL2009_21.pdf))
- CEL 22 (2009) Safe Intravenous Administration of Vinca Alkaloids The Scottish Government Health Directorates, Healthcare Planning and Policy. ([www.sehd.scot.nhs.uk/mels/CEL2009\\_22.pdf](http://www.sehd.scot.nhs.uk/mels/CEL2009_22.pdf))
- A Guide to the Safe Handling and Administration of Intrathecal Chemotherapy (August 2008). Welsh Assembly Governments (<http://new.wales.gov.uk/topics/health/ocmo/professionals/dental/publication/cdo-letters/chemotherapy/?lang=en>)
- A Guide to the Safe Handling and Administration of Vinca Alkaloids (August 2008). Welsh Assembly Governments (<http://new.wales.gov.uk/topics/health/ocmo/professionals/dental/publication/cdo-letters/vincaalkaloids/?lang=en>)
- The Welsh Assembly Government National Cancer Standards (<http://wales.gov.uk/topics/health/publications/health/guidance/nationalstandardscancer?lang=en>)
- ESMO and ASCO Recommendations for a Global Curriculum in Medical Oncology 2010 Update ([www.esmo.org/education-research/recommendations-for-a-global-core-curriculum-in-mo.html](http://www.esmo.org/education-research/recommendations-for-a-global-core-curriculum-in-mo.html))
- Joint Royal Colleges of Physicians Training Board (August 2010) Specialty Training Curriculum for Medical Oncology ([www.jrcptb.org.uk](http://www.jrcptb.org.uk))
- Skills for Health Application Tools (<https://tools.skillsforhealth.org.uk/>)

# APF Mapping Tables

---

This following tables list the knowledge, skills, experience and behaviours recommended to demonstrate the APF competencies for the Expert Professional Practice (EPP) and Collaborative Working Relationship (CWR) clusters mapped against the relevant APF developmental descriptors. It is intended primarily to support practitioners to develop their practice, but may be useful for portfolio preparation. All statements relate to the practitioner's area of practice speciality.

The competencies listed for "Advanced Stage I", "Advanced Stage II" and "Mastery" stage are additive, i.e. those at "Advanced Stage II" build on the competencies established in "Advanced Stage I". Practitioners are expected to demonstrate "Advanced Stage I" first before moving on to "Advanced Stage II". Those wishing to demonstrate "Advanced Stage II" will usually be expected to have demonstrated "Advanced Stage I" previously. Those wishing to demonstrate "Mastery" stage will usually be expected to have demonstrated "Advanced Stage II" previously.

A pharmacist starting to specialise in an area of Expert Professional Practice might be expected to be working towards attaining competencies at Advanced Stage I. A practitioner having attained Advanced Stage I in an area of Expert Professional Practice might be expected to be working towards attaining competencies at Advanced Stage II.

At Advanced Stage I practitioners are expected to build on the General Level Framework (see CoDEG's website: [www.codeg.org](http://www.codeg.org)) competencies and (for the relevant developmental descriptors) to demonstrate experience of caring for patients with disorders, pharmaceutical care issues and co-morbidities that are commonly found within Cancer Care.

At Advanced Stage II practitioners are expected to build on Advanced Stage I competencies and (for the relevant developmental descriptors) to demonstrate experience of caring for patients with complex co-morbidities or pharmaceutical care issues or those with more specialist conditions within Cancer Care.

At Mastery stage practitioners are expected to build on Advanced Stage II competencies and (for the relevant developmental descriptors) to demonstrate experience of caring for patients with complex co-morbidities or pharmaceutical care issues, or those with more specialist conditions within Cancer Care.

## Expert Professional Practice – Expert Skills and Knowledge (Cluster I.1)

Improving standards of pharmaceutical care for patients.

I.1 EXPERT SKILLS AND KNOWLEDGE	ADVANCED STAGE I	ADVANCED STAGE II
<p>APF competency developmental descriptors</p>	<p>Demonstrates general pharmaceutical skills and knowledge in core areas.</p> <p>In addition for patient focussed roles: Is able to plan, manage, monitor, advise and review general pharmaceutical care programmes for patients in core areas.</p>	<p>Demonstrates in-depth pharmaceutical skills and knowledge in defined area(s).</p> <p>In addition for patient focussed roles: Is able to plan, manage, monitor, advise and review in-depth/complex pharmaceutical care programmes for patients in defined area(s).</p>
<p>Recommended knowledge, skills, experience and behaviours</p>	<p>Application of core specialist knowledge of common disorders and common co-morbidities (including: aetiology, physiology, common signs and symptoms, epidemiology, risk factors).</p> <p>Application of core specialist knowledge of common medicines (including: place in therapy, mechanism of action, indications, common adverse effects and drug interactions, and precautions).</p> <p>Experience in application of basic knowledge of common drugs used in Cancer patients, including availability of formulations, compliance aids.</p> <p>Application of core specialist knowledge for the therapeutic management of common conditions and to ensure safe prescribing.</p> <p>Application of core specialist knowledge in the management of common pharmaceutical issues.</p> <p>Able to develop and implement plans for the pharmaceutical care of patients with common conditions.</p>	<p>Application of advanced knowledge of common disorders and co-morbidities and core specialist knowledge of more specialist disorders.</p> <p>Application of advanced knowledge and understanding of drugs, including high-risk drugs, unlicensed drugs and off-label use of drugs.</p> <p>Applies advanced knowledge of drugs used in cancer patients with complex medicines management needs, which may be complicated by other health and social care issues.</p> <p>Application of advanced knowledge for the therapeutic management of patients with complex co-morbidities and high risk factors, and to ensure safe prescribing for these patients.</p> <p>Leads the clinical management of cancer patients with complex pharmaceutical needs, which may include multiple morbidities as well as other health and social needs.</p> <p>Able to identify, manage and advise on complex pharmaceutical care issues.</p> <p>Able to develop and implement, and support/train others to develop and implement, plans for the pharmaceutical care of patients with complex pharmaceutical care issues and those with more complex conditions.</p>

## Expert Professional Practice – Expert Skills and Knowledge (Cluster I.1)

Improving standards of pharmaceutical care for patients.

I.1 EXPERT SKILLS AND KNOWLEDGE	ADVANCED STAGE I	ADVANCED STAGE II
<p>APF competency developmental descriptors</p>	<p>Demonstrates general pharmaceutical skills and knowledge in core areas.</p> <p>In addition for patient focussed roles: Is able to plan, manage, monitor, advise and review general pharmaceutical care programmes for patients in core areas.</p>	<p>Demonstrates in-depth pharmaceutical skills and knowledge in defined area(s).</p> <p>In addition for patient focussed roles: Is able to plan, manage, monitor, advise and review in-depth/complex pharmaceutical care programmes for patients in defined area(s).</p>
<p>Recommended knowledge, skills, experience and behaviours</p>	<p>Able to recognise, recommend and review appropriate monitoring of common disorders and medicines for the pharmaceutical care of patients.</p> <p>Contributes to management of cancer patients in order to reduce risk of adverse drug reactions (ADR), especially for patients who have experienced an ADR.</p> <p>Contributes to management of cancer patients in order to reduce risk of medicines related readmission in patients.</p> <p>Able to interpret and use common lab tests and/or disease markers for the pharmaceutical care of patients.</p> <p>Able to carry out medication review and develop and implement a medicines management plan for patients with common disorders and common pharmaceutical needs.</p> <p>Able to make recommendations on the pharmaceutical care of patients based on the evidence-base and/or best practice.</p> <p>Experience in application of recognised assessment tools to identify the needs of individual cancer patients including assessing risks in the context of patient situation, development and implementation of a care plan to meet those needs with evaluation of outcomes, supported by senior staff.</p>	<p>Actively identifies and manages patients with complex co-morbidities, pharmaceutical needs, interface or social issues that may impact on pharmaceutical care.</p> <p>Able to advise on the appropriate monitoring of disorders and medicines for patients with complex pharmaceutical care needs.</p> <p>Able to interpret and use complex/specialist lab tests and/or disease markers for the pharmaceutical care of patients.</p> <p>Able to carry out medication review and develop and implement a medicines management plan for patients with complex co-morbidities, high risk disorders and/or complex pharmaceutical needs.</p> <p>Able to make recommendations on the pharmaceutical care of complex patients based on the evidence-base and/or best practice. (also see 3 below)</p> <p>Able to interpret and use complex/specialist lab tests and/or disease markers for the pharmaceutical care of patients.</p>

## Expert Professional Practice – Expert Skills and Knowledge (Cluster I.1)

Improving standards of pharmaceutical care for patients.

I.1 EXPERT SKILLS AND KNOWLEDGE	ADVANCED STAGE I	ADVANCED STAGE II
<p>APF competency developmental descriptors</p>	<p>Demonstrates general pharmaceutical skills and knowledge in core areas.</p> <p>In addition for patient focussed roles: Is able to plan, manage, monitor, advise and review general pharmaceutical care programmes for patients in core areas.</p>	<p>Demonstrates in-depth pharmaceutical skills and knowledge in defined area(s).</p> <p>In addition for patient focussed roles: Is able to plan, manage, monitor, advise and review in-depth/complex pharmaceutical care programmes for patients in defined area(s).</p>
<p>Recommended knowledge, skills, experience and behaviours</p>	<p>Able to provide a full clinical service to cancer patients in community or hospital settings with complex pharmaceutical needs e.g. hospices, home settings, supported by senior staff.</p> <p>Able to describe the main principles of the relevant key papers and national documents.</p> <p>Able to follow relevant policies and local and national guidance.</p> <p>Able to advise others in the team on the management of patients with common pharmaceutical care issues.</p>	<p>Able to carry out medication review and develop and implement a medicines management plan for patients with complex co-morbidities, high risk disorders and/or complex pharmaceutical needs.</p> <p>Able to make recommendations on the pharmaceutical care of complex patients based on the evidence-base and/or best practice. (also see 3 below)</p> <p>Identifies and manages cancer patients in order to reduce risk of adverse drug reactions (ADR) and medicines related readmission in patients where medicines have contributed to a recent or the current admission.</p> <p>Applies the main principles of key papers, policies, national documents, and local and national guidance to the care of patients with complex co-morbidities, high risk disorders and/or complex pharmaceutical needs.</p> <p>Advises others in the team on the management of patients with complex pharmaceutical care issues.</p> <p>Able to advise on the choice and use of relevant specialist resources to resolve complex pharmaceutical care issues.</p> <p>Applies and advises on pharmacokinetic and pharmacodynamic principles to ensure safe and effective prescribing.</p>

## Expert Professional Practice – Expert Skills and Knowledge (Cluster I.1)

Improving standards of pharmaceutical care for patients.

I.1 EXPERT SKILLS AND KNOWLEDGE	ADVANCED STAGE I	ADVANCED STAGE II
<p>APF competency developmental descriptors</p>	<p>Demonstrates general pharmaceutical skills and knowledge in core areas.</p> <p>In addition for patient focussed roles: Is able to plan, manage, monitor, advise and review general pharmaceutical care programmes for patients in core areas.</p>	<p>Demonstrates in-depth pharmaceutical skills and knowledge in defined area(s).</p> <p>In addition for patient focussed roles: Is able to plan, manage, monitor, advise and review in-depth/complex pharmaceutical care programmes for patients in defined area(s).</p>
<p>Recommended knowledge, skills, experience and behaviours</p>	<p>Liaises across care interfaces to optimise medicines management in the transfer of care from different settings.</p> <p>Able to describe and use relevant resources for the pharmaceutical care of patients.</p> <p>Able to apply and comply with the relevant legal, ethical, professional and organisational policies and procedures and codes of conduct issues that have implications for the pharmaceutical care of patients.</p> <p>Able to apply pharmacoeconomic principles and support drug expenditure analysis work.</p>	<p>Able to consult with, educate and advise patients, carers, pharmacy staff, students, medical staff, nursing staff and other allied healthcare professionals (AHPs) effectively on complex pharmaceutical care issues and related relevant healthcare issues within and outside the Trust.</p> <p>Able to support other staff in advanced aspects of specialist pharmaceutical and related care.</p> <p>Able to influence the structure of the service, the system of care, and the roles of the healthcare professionals and other relevant teams, disciplines or agencies involved in patient care.</p> <p>Able to advise on the relevant legal, ethical, professional and organisational policies and procedures and codes of conduct issues that have implications for the pharmaceutical care of patients.</p> <p>Demonstrates understanding of the ethics of compliance, consent and patient advocacy for cancer patients.</p> <p>Interprets, undertakes and communicates drug expenditure analysis and advises on relevant pharmaco-economic issues.</p>

## Expert Professional Practice – Delivery of Professional Expertise (Cluster I.2)

Improving standards of pharmaceutical care for patients.

I.2 DELIVERY OF PROFESSIONAL EXPERTISE	ADVANCED STAGE I	ADVANCED STAGE II
APF competency developmental descriptors	Demonstrates accountability for delivering professional expertise and direct service provision as an individual.	Demonstrates accountability for the delivery of professional services and expertise via a team or directly to groups of patients/clients/users.
Recommended knowledge, skills, experience and behaviours	<p>Able to provide a clinical pharmacy service and deliver effective pharmaceutical care to patients with common pharmaceutical needs.</p> <p>Undertakes prescription verification of anti-cancer agents according to local and national standards.</p> <p>Monitors prescribing quality and addresses and resolves issues identified with the appropriate member(s) of the MDT.</p> <p>Contributes to service development, clinical audit and evaluation of the pharmacy service.</p> <p>Ensures that appropriate patient documentation is maintained.</p>	<p>Responsible for the provision of a clinical pharmacy service and the delivery of effective pharmaceutical care to patients with complex co-morbidities or pharmaceutical needs.</p> <p>Monitors prescribing quality and addresses and resolves any issues identified within the locality.</p> <p>Initiates and leads service development, clinical audit and evaluation of the pharmacy service in a defined area of practice.</p> <p>Actively involved in the development of medicines-related aspects of patient documentation systems.</p> <p>Advises on and manages the entry of new drugs.</p>

## Expert Professional Practice – Reasoning and Judgement (Cluster I.3)

Improving standards of pharmaceutical care for patients.

I.3 REASONING AND JUDGEMENT	ADVANCED STAGE I	ADVANCED STAGE II
APF competency developmental descriptors	<p>Demonstrates ability to use skills in a range of routine situations requiring analysis or comparison of a range of options.</p> <p>Recognises priorities when problem-solving and identifies deviations from the normal pattern.</p>	<p>Demonstrates ability to use skills to make decisions in complex situations where there are several factors that require analysis, interpretation and comparison.</p> <p>Demonstrates an ability to see situations holistically.</p>
Recommended knowledge, skills, experience and behaviours	<p>Able to recognise and resolve basic problems.</p> <p>Monitors patient visits under supervision/mentorship.</p> <p>Able to recommend justifiable courses of action.</p> <p>Demonstrates accurate reasoning.</p> <p>Able to make decisions with limited information.</p> <p>Able to critically appraise and interpret published papers.</p> <p>Able to make decisions in a timely manner.</p> <p>Able to prioritise problems.</p> <p>Able to assess prescriptions or work for adherence to local/national guidelines.</p> <p>Recognises own limitations and able to refer appropriately.</p>	<p>Recognises, evaluates and resolves complex problems.</p> <p>Able to appraise information, make an informed decision with the evidence available and be able to justify/defend the decision to others, including in situations where evidence is lacking.</p> <p>Recognises limitations of supporting data.</p> <p>Able to present and explain a critical appraisal of published papers.</p> <p>Is aware of the limitations of some research to non-research settings.</p> <p>Demonstrates an ability to see situations holistically.</p> <p>Able to take into consideration different values and views when making decisions.</p> <p>Able to refer appropriately to others within and outside own team.</p>



## Expert Professional Practice – Professional Autonomy (Cluster I.4)

Improving standards of pharmaceutical care for patients.

I.4 PROFESSIONAL AUTONOMY	ADVANCED STAGE I	ADVANCED STAGE II
APF competency developmental descriptors	Is able to follow legal, ethical, professional and organisational policies/procedures and codes of conduct.	Is able to take action based on own interpretation of broad professional policies/procedures where necessary.
Recommended knowledge, skills, experience and behaviours	<p>Able to follow organisation guidance related to the local service.</p> <p>Follows legal, ethical and organisational policy and procedures and codes of conduct.</p> <p>Contributes to the development of policies and procedures specifically for the local service, under supervision.</p> <p>Able to identify areas of practice in requiring pharmaceutical input and development.</p> <p>Able to work for short periods of time in the absence of senior support.</p> <p>Demonstrates awareness and knowledge about issues relating to record keeping, confidentiality and communication (including the Data Protection Act, and Caldicott guidance).</p> <p>Demonstrates awareness and knowledge about legislation pertaining to consent.</p>	

## Expert Professional Practice – Professional Autonomy (Cluster I.4)

Improving standards of pharmaceutical care for patients.

I.4 PROFESSIONAL AUTONOMY	ADVANCED STAGE I	ADVANCED STAGE II
APF competency developmental descriptors	Is able to follow legal, ethical, professional and organisational policies/procedures and codes of conduct.	Is able to take action based on own interpretation of broad professional policies/procedures where necessary.
<p><b>Recommended knowledge, skills, experience and behaviours</b></p>	<p>Demonstrates awareness and application of cultural and gender issues in specialist area, application of the principles and practices of anti-discriminatory practice.</p> <p>Understands the broad remit of the Equality Act 2010 and promotes equality in the workplace.</p> <p>Understands and adheres to legal frameworks including the Mental Capacity Act, Medicines Act, Controlled Drugs legislation etc.</p> <p>Understands the broad remit and powers of the mental capacity act (MCA).</p> <p>Demonstrates an understanding of the legal requirements surrounding the use of medicines as detailed in the MCA.</p> <p>Demonstrates an understanding of the issues involved, and legal stance of covert administration.</p>	<p>Develops policies, procedures and treatment guidelines specifically for the local service.</p> <p>Involved in the development and implementation supplementary/independent prescribing in organisations where this is being developed.</p> <p>Participates in organisation or service -wide multidisciplinary groups with respect to pharmacy issues.</p> <p>Able to work for extended periods of time in the absence of senior support.</p>

## Collaborative Working Relationships – Communication (Custer 2.1)

Is able to communicate, establish and maintain professionally-driven working relationships and gain the co-operation of others.  
Including ability to: Persuade; Motivate; Negotiate; Empathise; Provide reassurance; Listen; Influence and Networking skills; Presentation skills.

2.1 COMMUNICATION		ADVANCED STAGE I	ADVANCED STAGE II
APF competency developmental descriptors		<p>Demonstrates use of appropriate communication to gain the co-operation of relevant stakeholders (including patients, senior and peer colleagues, and other professionals where possible).</p> <p>Demonstrates ability to communicate where the content of the discussion is explicitly defined.</p>	<p>Demonstrates use of appropriately selected communication skills to gain co-operation of small groups of relevant stakeholders within the organisation.</p> <p>Demonstrates ability to communicate where the content of the discussion is based on professional opinion.</p>
Recommended knowledge, skills, experience and behaviours	Persuade	<p>Able to persuade others within the MDT about individual episodes of care.</p> <p>Able to engage patients in meaningful discussions about medicines, and compliance.</p>	<p>Able to persuade or influence the MDT regarding individual complex clinical or technical issues.</p> <p>Able to engage patients in meaningful discussions about medicines, and compliance.</p> <p>Able to persuade or influence staff with respect to organisational change, research, guidelines and protocols, in line with medicines management agenda.</p>
	Motivate	<p>Demonstrates self-motivation.</p> <p>Able to motivate other staff in the pharmacy team.</p>	<p>Motivates members of the pharmacy team (e.g. to follow a guideline, collect data, to improve the quality of care, to identify areas of practice for development and improvement).</p>

## Collaborative Working Relationships – Communication (Cluster 2.1)

Is able to communicate, establish and maintain professionally-driven working relationships and gain the co-operation of others.

Including ability to: Persuade; Motivate; Negotiate; Empathise; Provide reassurance; Listen; Influence and Networking skills; Presentation skills.

2.1 COMMUNICATION		ADVANCED STAGE I	ADVANCED STAGE II
APF competency developmental descriptors		<p>Demonstrates use of appropriate communication to gain the co-operation of relevant stakeholders (including patients, senior and peer colleagues, and other professionals where possible).</p> <p>Demonstrates ability to communicate where the content of the discussion is explicitly defined.</p>	<p>Demonstrates use of appropriately selected communication skills to gain co-operation of small groups of relevant stakeholders within the organisation.</p> <p>Demonstrates ability to communicate where the content of the discussion is based on professional opinion.</p>
Recommended knowledge, skills, experience and behaviours	Negotiate	<p>Negotiates on pharmaceutical care or technical issues for individual patients.</p> <p>Negotiates issues about teamwork and workloads (e.g. rotas, staffing, training requirements).</p> <p>Negotiates simple treatment issues with patients &amp; MDT.</p>	<p>Negotiates on pharmaceutical care or technical issues for groups of patients.</p> <p>Negotiates issues between the speciality team and pharmacy.</p> <p>Able to negotiate on financial issues.</p> <p>Able to negotiate complex treatment issues with patients and MDT.</p>
	Empathise/ Provide Reassurance	<p>Communicates in an empathetic and respectful manner with patients, carers and staff. Uses appropriate verbal and body language.</p> <p>Able to communicate sensitive information and advice to patients in a professional manner and to acknowledge boundaries in behaviour.</p> <p>Able to reassure individuals appropriately.</p>	<p>Communicates in an empathetic and respectful manner with patients, carers and staff in complex situations. Uses appropriate verbal and body language.</p> <p>Manages, mentors and supervises staff in an empathetic manner.</p> <p>Able to reassure groups appropriately.</p>

## Collaborative Working Relationships – Communication (Cluster 2.1)

Is able to communicate, establish and maintain professionally-driven working relationships and gain the co-operation of others.

Including ability to: Persuade; Motivate; Negotiate; Empathise; Provide reassurance; Listen; Influence and Networking skills; Presentation skills.

2.1 COMMUNICATION		ADVANCED STAGE I	ADVANCED STAGE II
APF competency developmental descriptors		<p>Demonstrates use of appropriate communication to gain the co-operation of relevant stakeholders (including patients, senior and peer colleagues, and other professionals where possible).</p> <p>Demonstrates ability to communicate where the content of the discussion is explicitly defined.</p>	<p>Demonstrates use of appropriately selected communication skills to gain co-operation of small groups of relevant stakeholders within the organisation.</p> <p>Demonstrates ability to communicate where the content of the discussion is based on professional opinion.</p>
Recommended knowledge, skills, experience and behaviours	Listen	Able to effectively listen and respond to patients, carers, colleagues and members of the MDT.	<p>Demonstrates effective listening skills with patients, carers, visitors, members of the MDT and/or colleagues.</p> <p>Able to effectively listen to groups of patients, carers, visitors, members of the MDT and/or colleagues.</p>
	Influence	<p>Able to use appropriate communication to gain the co—operation of individual patients, colleagues and clinicians.</p> <p>Able to positively influence junior staff within the local clinical pharmacy team to develop and deliver a higher quality of service.</p>	<p>Able to use appropriately selected communication skills to gain the co—operation of small groups of patients, colleagues, senior clinicians and managers within the organisation.</p> <p>Able to positively influence staff delivering the local clinical services. To increase the MDTs awareness of medicine management issues.</p> <p>Demonstrates assertive behaviour.</p> <p>Able to advocate for others.</p> <p>Proactively influences developments in pharmacy services to meet the needs of patients.</p>

## Collaborative Working Relationships – Communication (Cluster 2.1)

Is able to communicate, establish and maintain professionally-driven working relationships and gain the co-operation of others.

Including ability to: Persuade; Motivate; Negotiate; Empathise; Provide reassurance; Listen; Influence and Networking skills; Presentation skills.

2.1 COMMUNICATION		ADVANCED STAGE I	ADVANCED STAGE II
APF competency developmental descriptors		<p>Demonstrates use of appropriate communication to gain the co-operation of relevant stakeholders (including patients, senior and peer colleagues, and other professionals where possible).</p> <p>Demonstrates ability to communicate where the content of the discussion is explicitly defined.</p>	<p>Demonstrates use of appropriately selected communication skills to gain co-operation of small groups of relevant stakeholders within the organisation.</p> <p>Demonstrates ability to communicate where the content of the discussion is based on professional opinion.</p>
Recommended knowledge, skills, experience and behaviours	Networking Skills	<p>Is a member of the relevant national clinical speciality group or other local/national associations that provide an appropriate level of support.</p> <p>Is a fully integrated member of the local MDT.</p> <p>Attends relevant external/educational meetings.</p> <p>Able to network effectively.</p>	<p>Is a participating member of the relevant national clinical speciality group.</p> <p>Participates in local network groups (or equivalent).</p> <p>Participating member of working groups within the local service.</p> <p>Attends relevant national/international conferences.</p>
	Presentation Skills	<p>Presents effectively to pharmacy and the multi-disciplinary team (MDT).</p> <p>Communication is always clear, precise and appropriate.</p>	<p>Presents effectively to senior MDT including consultant level.</p> <p>Presents effectively at clinical speciality group meetings.</p>

## Collaborative Working Relationships – Teamwork and Consultation (Cluster 2.2)

Is able to communicate, establish and maintain professionally-driven working relationships and gain the co-operation of others.  
Including ability to: Persuade; Motivate; Negotiate; Empathise; Provide reassurance; Listen; Influence and Networking skills; Presentation skills.

2.2 TEAMWORK AND CONSULTATION		ADVANCED STAGE I	ADVANCED STAGE II
APF competency developmental descriptors		<p>Demonstrates ability to work as a member of a team.</p> <p>Recognises personal limitations and refers to more appropriate colleague(s) when necessary.</p>	<p>Demonstrates ability to work as an acknowledged member of a multidisciplinary team.</p> <p>Consulted within the organisation for advice which requires in-depth professional expertise.</p>
Recommended knowledge, skills, experience and behaviours	Teamwork	<p>Able to work effectively as part of clinical speciality team, and within the MDT.</p> <p>Able to explain the roles of the members of the MDT, and values other members of the team.</p> <p>Recognises situations outside of own experience or competence and effectively refers to a more appropriate member of the team.</p> <p>Demonstrates initiative in own work.</p> <p>Demonstrates ability to effectively delegate work/tasks to other members of the team and is willing to take on work/tasks delegated by senior staff.</p>	<p>Demonstrates the ability to work as an acknowledged member of an MDT, and as part of a clinical pharmacy team.</p> <p>Shares expertise with both pharmacy and clinical speciality colleagues.</p> <p>Recognition of expertise by the local service.</p> <p>Participates in MDT working groups looking into service development or clinical guidelines development.</p>

## Collaborative Working Relationships – Teamwork and Consultation (Cluster 2.2)

Is able to communicate, establish and maintain professionally-driven working relationships and gain the co-operation of others.  
Including ability to: Persuade; Motivate; Negotiate; Empathise; Provide reassurance; Listen; Influence and Networking skills; Presentation skills.

2.2 TEAMWORK AND CONSULTATION		ADVANCED STAGE I	ADVANCED STAGE II
APF competency developmental descriptors		<p>Demonstrates ability to work as a member of a team.</p> <p>Recognises personal limitations and refers to more appropriate colleague(s) when necessary.</p>	<p>Demonstrates ability to work as an acknowledged member of a multidisciplinary team.</p> <p>Consulted within the organisation for advice which requires in-depth professional expertise.</p>
Recommended knowledge, skills, experience and behaviours	Consultation	<p>Recognises a situation outside competence and refers to supervising pharmacist (appropriate pharmaceutical problems are always appropriately referred).</p>	<p>Receives and effectively responds to requests for advice in specialist field from within the specialist area within the Trust, teaches junior staff to do so.</p> <p>Actively participates in multi-disciplinary task forces/service developments.</p> <p>Participates in clinical speciality group meetings (including networks).</p>



# Syllabus for Advanced Cancer Care Pharmacists

---

This syllabus is a recommended list of the specific elements of pharmaceutical and related care that a practitioner developing towards advanced and consultant level will need to know about and apply in their practice in Cancer Care.

*These examples are not about non-medical prescribing or administration of medicines, which falls outside the scope of this document. Their purpose is to be used as an outline intended to guide practice rather than to be a prescriptive list that has to be adhered to in all cases.*

## Advanced Stage I

### Scope

Entry Point: Diploma in General Practice Pharmacy and Statement of Completion of General Level Framework (e.g. Band 6 (DipGPP)) or appropriate proof of equivalent qualification and practice).

Completion Point: Statement of Completion of Advanced Stage I competencies (including application of knowledge during experience in the defined area of practice).

### Description

Whilst working towards Advanced Stage I the aim is for practitioners to develop and deliver competent clinical care with a focus on Cancer Care.

The individual works towards becoming competent at delivering a clinical pharmacy service to patients with common disorders in surgery through experience of delivering a service to these patients.

## Advanced Stage II

### Scope

Entry Point: Statement of Completion of Advanced Stage I competencies with (including application of knowledge during experience in the defined area of practice).

Completion Point: Statement of Completion of Advanced Stage II competencies (including application of advanced knowledge during experience in Cancer Care area(s)).

### Description

Whilst working towards Advanced Stage II the aim is for practitioners to continue to develop advanced knowledge and skills in order to deliver good quality clinical care to the various groups of Cancer Care patients. The practitioner is expected to be an integrated member of the wider multi-professional team and as such works alongside other professionals to achieve the aims of the team, leading where appropriate.

## Mastery

### Scope

**Entry Point:** Statement of Completion of Advanced Stage II competencies with (including application of knowledge during experience in the defined area of Cancer Care).

**Completion Point:** Statement of Completion of Mastery stage competencies (including application of advanced knowledge during experience in Cancer Care area or areas).

### Description

Whilst working towards Mastery stage the aim is for practitioners to continue to develop advanced knowledge and skills in order to deliver good quality clinical care to the various groups of Cancer Care. The practitioner is expected to be an integrated member of the wider multi-professional team and as such works alongside other professionals to achieve the aims of the team, leading where appropriate.

The following tables are the syllabus for Cancer Care. For illustrative purposes the syllabus has been laid out here in BNF order, with additional categories. Categories have been left blank where there are no syllabus items. A group may decide that another way of ordering the syllabus is more relevant to their expert practice, for example according to the medicines use process or a medicines pathway. The final column of the table shows whether the syllabus item is expected at Advanced Stage I, Advanced Stage II or Mastery stage.

It is acknowledged that practitioners may have already covered some of this syllabus at general level. Practitioners are reminded that a piece of evidence of a specific knowledge should not be resubmitted to achieve the requirements for another award as credit can only be awarded once for each piece of evidence. However, knowledge gained previously could be used in conjunction with experience to develop and demonstrate competency at Advanced Stage I, Advanced Stage II or Mastery level of the APF.

Specialist knowledge is defined here as knowledge that is specific to surgery, and is not generally used outside this area. Generalist knowledge is defined here as common knowledge that may be pertinent to other areas of practice outside Cancer Care.

- 1 Gastrointestinal System
- 2 Cardiovascular System
- 3 Respiratory System
- 4 Central Nervous System
- 5 Infections
- 6 Endocrine System
- 7 Obstetrics, Gynaecology and Urinary-Tract Disorders
- 8 Malignant Disease and Immunosuppression
- 9 Nutrition and Blood
- 10 Musculoskeletal and Joint Diseases
- 11 Eye
- 12 Ear, Nose and Oropharynx
- 13 Skin
- 14 Immunological Products and Vaccines
- 15 Anaesthesia
- 16 Liver Disease
- 17 Renal Impairment
- 18 Pregnancy
- 19 Breast-Feeding
- 20 Older People
- 21 HIV
- 22 Toxicology
- 23 Parenteral Therapy
- 24 Paediatrics
- 25 Palliative and End Of Life Care
- 26 Clinical Trials
  
- 27 Other Issues in Cancer Care

I Gastrointestinal System		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common GI cancers e.g. oesophageal, gastric, colon, anal, hepatocellular, biliary and pancreatic cancers.	S	Adv I
Demonstrates understanding of the basic pathophysiology and risk factors for chemotherapy and radiotherapy-induced nausea and vomiting.	S	Adv I
Demonstrates understanding of the basic pathophysiology and risk factors for chemotherapy and radiotherapy-induced mucositis and oesophagitis.	S	Adv I
Demonstrates understanding of the mechanism of action, characteristics and clinical use of treatments for chemotherapy and radiotherapy-induced nausea and vomiting.	S	Adv I
Demonstrates understanding of the mechanism of action, characteristics and clinical use of treatments for chemotherapy and radiotherapy-induced diarrhoea.	S	Adv I
Demonstrates understanding of mechanisms of action, characteristics and clinical use of anti-emetics, pro-kinetics, laxatives and anti-diarrhoeals.	G	Adv I
Demonstrates understanding of mechanism, characteristics and pharmacological management of bowel obstruction.	G	Adv I
Demonstrates understanding of the role of the dietician and speech and language therapist in managing patients with dysphagia.	G	Adv I
Demonstrates understanding of the the basic pathophysiology and management options for dysphagia and its implications for medicines management.	G	Adv I
Demonstrates understanding of the mechanism of action, characteristics and clinical use of treatments for undernourishment, anorexia, profound weight loss and cachexia.	S	Adv I
Demonstrates understanding of the uses of, need for and implications of PEG/RIG placement.	G	Adv I

## 2 Cardiovascular System

	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Understands the principles, characteristics and clinical use of intravenous fluids, the differences between crystalloids and the various colloids (e.g. proteins, starches, dextrans).	G	Adv I
Understands the effect of the administration of fluid (or dehydration states) on various cardiovascular parameters (e.g. venous return, central venous pressure, cardiac output and arterial blood pressure).	G	Adv I
Demonstrates understanding of incidence, pathophysiology, and management of pericardial effusion.	S	Adv I
Understands the available methods for monitoring of cardiovascular function (e.g. ECHO, MUGA, ECG).	G	Adv I
Demonstrates an understanding of the basic pathophysiology and the mechanism of treatment options for thrombo-embolic disorders e.g. pulmonary embolism, deep vein thrombosis (DVT).	G	Adv I
Demonstrates understanding of the mechanism of action, characteristics and use of diuretics with hydration regimens.	G	Adv I
Demonstrates understanding of the basic pathophysiology and management options for oedema (peripheral and pulmonary) and heart failure (acute and chronic) in patients having hydration regimens.	G	Adv I
Demonstrates understanding of the basic pathophysiology and management options for drug-induced cardiac toxicity.	G	Adv I
Demonstrates understanding of the basic pathophysiology and management options for primary and secondary prevention of drug-induced cardiovascular toxicity.	G	Adv I
Demonstrate knowledge/understanding of systemic therapies that are potentially cardiotoxic.	S	Adv I

## 3 Respiratory System

	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common lung cancers, e.g. Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), mesothelioma.	S	Adv I
Demonstrates understanding of the basic pathophysiology and management options for drug-induced pulmonary toxicity.	G	Adv I
Demonstrates understanding of the basic pathophysiology and management options for primary and secondary prevention of drug-induced pulmonary toxicity.	G	Adv I
Demonstrates understanding of incidence, pathophysiology, and management of pleural effusion.	S	Adv I
Able to describe the mechanism of action, evidence base, and use of mucolytics/mucokinetics.	G	Adv I
Understand the role of the physiotherapist in supporting patients with respiratory primary or secondary cancer or respiratory symptoms.	G	Adv I
Demonstrate knowledge/understanding of systemic therapies that are potentially toxic to the respiratory system.	S	Adv I

#### 4 Central Nervous System

	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common CNS cancers, e.g. glioma, neuroblastoma.	S	Adv I
Demonstrate knowledge/understanding of the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for brain metastases and in which cancers they commonly occur.	S	Adv I
Demonstrates an understanding of the implications of raised intracranial pressure and methods of drug management.	S	Adv I
Demonstrates understanding of common methods of assessing cognitive function.	G	Adv II
Demonstrates understanding of the broad remit and powers of the mental capacity act (MCA).	G	Adv II
Demonstrates understanding of the medico-legal issues involved, and legal stance, of covert administration and consent.	G	Adv II
Demonstrates understanding of basic pathophysiology and common treatment of vestibular disorders e.g. in head and neck cancers.	S	Adv I
Demonstrates understanding of the symptoms, basic pathophysiology and management options in primary or secondary cancer induced epilepsy.	S	Adv I
Demonstrates understanding of the potential interactions between psychiatric illness and epilepsy, and the psychotropics and anticonvulsants.	G	Adv I
Demonstrates understanding of the basic pathophysiology of pain.	G	Adv I
Demonstrates understanding of the treatment options for acute pain.	G	Adv I
Demonstrates understanding of the drug treatment options for chronic and neuropathic pain.	G	Adv I
Demonstrates understanding of the complex issues around comorbidities and selection of pain management option (drug and non-drug) in cancer patients.	S	Adv II
Demonstrate an understanding and knowledge of local and national guidelines for intra-theccal chemotherapy.	G	Adv I
Awareness of drugs which are given intra-theccally, the timing of intra-theccal administration in relation to other drugs in the regimen, and training requirements of the multidisciplinary team.	G	Adv I

5 Infections		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate understanding of factors predisposing cancer patients to infectious complications, including how to prevent, minimise, or treat the occurrence of such factors.	G	Adv I
Demonstrates understanding of the mechanism of action, characteristics and use of antibacterial agents in the management of neutropenic sepsis.	S	Adv I
Demonstrates understanding of the mechanism of action, characteristics and use of antibacterial agents in the management of bacterial infections (including spectrums of activity).	G	Adv I
Demonstrates understanding of the mechanism of action, characteristics and use of antiviral agents in the management of viral infections.	G	Adv I
Demonstrates understanding of the mechanism of action, characteristics and use of antifungal agents in the management of fungal infections.	G	Adv I
Demonstrate an understanding of central venous access device (CVAD) related infections and their management.	S	Adv I
Demonstrate an understanding of pathophysiology, characteristics and management of mucositis and stomatitis (drug and non-drug management).	S	Adv I
Understands and is able to describe the process of antimicrobial resistance.	G	Adv I
Understands the theory behind selective barrier nursing.	G	Adv I
Demonstrate an understanding of the mechanism of action and characteristics of the use of antibacterials, antifungals and antivirals in transplant patients.	S	Adv II
Demonstrate an understanding of the mechanism of action of granulocyte colony stimulating factors (GCSF) and criteria for use of GCSF for treatment and prophylaxis (primary and secondary).	S	Adv I
Ability to describe local antibiotic prophylaxis with specific cancer treatments (surgery, systemic or radiotherapy).	S	Adv I
A knowledge and understanding of isolation measures.	G	Adv I

6 Endocrine System		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common endocrine cancers, e.g. pancreatic, adrenal, thyroid, neuroendocrine.	S	Adv II
Demonstrate an understanding of pathophysiology, characteristics and management of steroid-induced diabetes and use of oral and injectable hypoglycaemic agents.	G	Adv I
Demonstrates understanding of the basic pathophysiology, characteristics and treatment of SIADH	S	Adv I
Knowledge of the role that hormones play in malignant disease, including understanding of how they can be involved in the growth and spread of the disease as well as how their action can be curtailed. E.g. Tamoxifen in breast cancer	S	Adv I
Knowledge of anti-cancer agent toxicity to endocrine system, and its treatment.	S	Adv II

## 7 Obstetrics, Gynaecology and Urinary-Tract Disorders

	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common gynaecological cancers, e.g. ovarian, uterine, cervical, vulvar, vaginal, endometrial.	S	Adv I
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common urological cancers, e.g. bladder, prostate, renal cell, urothelial, penile.	S	Adv I
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common germ cell cancers, e.g. testicular, seminoma, non-seminomatous germ cell tumours.	S	Adv I
Demonstrate knowledge/understanding of the use of localised radiotherapy, e.g. brachytherapy, seed implants.	S	Adv II
Demonstrate knowledge/understanding of the use of intra-vesicular chemotherapy for superficial bladder cancer.	S	Adv I
Demonstrates understanding of and monitors renal function / dysfunction (acute or chronic)	G	Adv I
Demonstrates understanding of the basic pathophysiology and risk factors for the development of sexual dysfunction.	S	Adv II
Demonstrates understanding of the mechanism of action, characteristics and clinical use of treatments of sexual dysfunction.	S	Adv II
Understands need for fertility preservation e.g. egg/sperm collection.	S	Adv II



## 8 Malignant Disease and Immunosuppression

	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, risk factors and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common cancers not covered elsewhere in the syllabus, e.g. Breast cancer, paediatric oncology.	S	Adv I
Demonstrates understanding of the biology of cancer including the cell cycle, classification, mechanism of action and scheduling of systemic therapy, monitoring response to treatment and disease progression.	S	Adv I
Demonstrates understanding/knowledge of first line and relapsed regimens used within scope of practice.	S	Adv I
Demonstrates understanding of causes of cancer and the disease process, key roles of the multidisciplinary oncology, haematology and palliative care teams, structure of cancer services (e.g. units, centres, networks), and holistic care of the cancer patient.	S	Adv I
Demonstrates understanding of common terminology used in cancer, staging systems, tumour markers, and performance status.	S	Adv I
Demonstrates ability to accurately verify chemotherapy prescriptions within scope of practice according to local and national guidelines.	S	Adv I
Demonstrates an understanding of the mode of action of anti-cancer medicines.	S	Adv I
Demonstrates understanding/knowledge of management of common toxicities of cancer treatment e.g. Cardiovascular, mucositis, alopecia, neutropenia, skin reactions (e.g. Palmar Plantar Erythrodysesthesia), nausea & vomiting use of mesna, folinic acid rescue, ifosfamide encephalopathy, hydration regimens and management of fluid balance, electrolyte disturbances, alkalinisation of urine, graft versus host disease (GVHD), endocrine & metabolic, hepatotoxicity, nephrotoxicity, neurotoxicity, pulmonary, infertility.	S	Adv I
Demonstrates understanding/knowledge of management of oncological emergencies e.g. tumour lysis syndrome, hypercalcaemia of malignancy, spinal cord compression, superior vena cava obstruction, raised intracranial pressure, neutropenic sepsis, hypersensitivity reactions, extravasation, haemorrhage.	S	Adv I
Demonstrates understanding/knowledge of management of common symptoms/complications of cancer e.g. pain, diarrhoea, constipation, nausea and vomiting, infections, dyspnoea, bleeding & thrombosis, obstruction, bone complications, anaemia.	S	Adv I
Demonstrates understanding/knowledge of the psychosocial aspects and impact of cancer on the patient and their family.	S	Adv I
Demonstrates understanding/knowledge of special issues in the diagnosis and treatment of cancers in adolescents and young adults.	S	Adv I
Demonstrates understanding/knowledge of systemic therapy dose calculations including body surface area (BSA) determination.	S	Adv I
Demonstrates understanding/knowledge of pharmacokinetics, pharmaco-genomics and pharmacology of anti-cancer agents.	S	Adv I
Demonstrate understanding/knowledge of biologic therapy, including combinations with chemotherapy, toxicity, e.g. monoclonal antibodies, tyrosine kinase inhibitors.	S	Adv I
Demonstrate understanding/knowledge of other targeted molecular therapies, e.g. tumour vaccines, cellular therapy.	S	Adv II

## 9 Nutrition and Blood

	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common haematological cancers e.g. leukaemias, myeloma, lymphomas.	S	Adv I
Demonstrate knowledge/understanding of bone marrow transplantation.	S	Adv I
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common AIDS-associated malignancies.	S	Adv I
Demonstrate an understanding of when to use appropriate blood products e.g. platelets, packed cells.	S	Adv I
Demonstrate knowledge of mechanism of action and therapeutic uses of use of granulocyte colony stimulating factor (GCSF) and erythropoietins.	S	Adv I
Able to describe and interpret the FBC.	G	Adv I
Demonstrates understanding of the pathophysiology of neutropenia, monitoring for and management options for treatment.	S	Adv I
Demonstrates awareness of medications that impact on neutropenia.	S	Adv I
Demonstrates understanding of the symptoms, basic pathophysiology and management options for anaemias.	G	Adv I
Knowledge of nutrition screening tools.	G	Adv I
Demonstrates understanding of the symptoms, basic pathophysiology and management options for malnutrition including electrolyte disturbances and the implications for medicines management.	G	Adv I
Demonstrates understanding of appropriate use of vitamin and mineral supplements for replacement therapy and for treatment purposes eg wound healing.	G	Adv I
Demonstrates understanding of the role of the dietician in the management of cancer patients.	G	Adv I
Demonstrates understanding of the role of enteral and parenteral nutrition in cancer patients.	S	Adv I
Demonstrates understanding of the role of clotting physiology and the effect of drugs upon it.	G	Adv I
Demonstrates understanding of the basic pathophysiology of disseminated intravascular coagulation (DIC).	G	Adv II
Demonstrates understanding of the interplay between coagulation and inflammation in sepsis and the role of activated protein C.	G	Adv II
Demonstrates understanding of the role and dosing of heparin, low molecular weight heparins and epoprostenol for different indications.	G	Adv II
Demonstrates understanding of the pathophysiology of thrombo-embolism and management options for both prophylaxis and treatment.	G	Adv I
Demonstrates understanding of the pharmacological support for malnutrition and anorexia/ cachetic patients.	S	Adv I
Understands the different options for feeding routes and options for feeding patients (parenteral and enteral nutrition, percutaneous endoscopically placed jejunostomy, percutaneous endoscopically placed gastrostomy, etc) and the implications they have for drug administration (absorption mechanisms, sites of absorption, interactions and side effects).	G	Adv I

10 Musculoskeletal and Joint Diseases		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common cancers e.g. sarcomas (bone, soft tissue, gastrointestinal stromal tumours (GIST)).	S	Adv I
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for bone metastases and in which cancers they commonly occur.	S	Adv I
Demonstrates understanding of the symptoms, basic pathophysiology and management options for hyperuricaemia (treatment & prevention).	G	Adv I
Demonstrates an understanding of the use of bisphosphonates and the implications of osteonecrosis of the jaw.	S	Adv I
Awareness of the use of cancer drugs for non-cancer indications e.g. rheumatoid arthritis, vasculitis.	G	Adv I

11 Eye		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common eye cancers e.g. retinoblastom	S	Adv II
Demonstrates understanding of the basic pathophysiology and management options for drug-induced optical toxicity.	S	Adv II
Demonstrates understanding of the use of ocular therapies to manage drug specific side effects.	S	Adv I
Demonstrates understanding of the use of chemotherapy drugs e.g. 5-fluorouracil and mitomycin, in ophthalmology.	S	Adv I

12 Ear, Nose and Oropharynx		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrates understanding of the basic pathophysiology and management options for drug-induced toxicity e.g. ototoxicity.	G	Adv I
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common head and neck cancers e.g. tongue, oropharynx, nasopharynx.	S	Adv I
Knowledge of the importance of oral care e.g. anti-fungals, pain relief, mouthwashes	S	Adv I

13 Skin		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for common skin cancers e.g. basal cell, squamous cell, melanoma.	S	Adv I
Demonstrates understanding of the basic pathophysiology and management options for drug-induced skin toxicity.	S	Adv I
Knowledge of acute and chronic skin reactions with radiotherapy and their treatment	S	Adv I

14 Immunological Products and Vaccines		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the use of vaccines and immunological products in the treatment of cancer, toxicity, monitoring, and handling.	S	Adv II
Demonstrate knowledge/understanding of new biological treatments on the horizon, research clinical trials.	S	Adv II
Demonstrate knowledge/understanding of the advice on vaccination to be given to patients with cancer, or being treated with anti-cancer agents – e.g. timing, use of live vaccines, etc.	S	Adv I

15 Anaesthesia		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the use of local anaesthesia for insertion of central lines, cannulation.	S	Adv I
Demonstrate knowledge/understanding of the use of anaesthetics for the administration of intrathecal drugs.	S	Adv I
Demonstrate knowledge/understanding of the use of anaesthetic drugs in palliative care.	S	Adv I

16 Liver Disease		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, pathophysiology, and management of ascites.	S	Adv I
Demonstrates understanding of and monitors liver function / dysfunction.	G	Adv I
Demonstrates understanding of the effect of medicines on liver function, particularly in relation to adverse effects.	G	Adv I
Demonstrates understanding of liver failure and liver metastases on drug clearance.	S	Adv I
Demonstrate knowledge/understanding of the epidemiology, risk factors, and the role of multimodality treatment (surgery, radiotherapy, systemic therapies) for liver metastases and in which cancers they commonly occur.	S	Adv I
Knowledge of chemo-embolisation.	S	Adv II

17 Renal impairment		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrates understanding and monitoring of renal function/dysfunction (acute/chronic).	G	Adv I
Demonstrates understanding of the effect of medicines on renal function (acute/chronic) and renal function on medicines.	G	Adv I
Demonstrates understanding of drug/dose alteration in different stages of renal impairment.	G	Adv I
Demonstrates understanding of the basic pathophysiology and risk factors for the development of renal failure (acute/chronic).	G	Adv I
Demonstrates understanding of the mechanism of action, characteristics and clinical use of treatments of renal failure.	S	Adv I

18 Pregnancy		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the role of multimodality treatment of cancers (surgery, radiotherapy, systemic therapies) in pregnant patients and the potential risks to the foetus.	S	Adv II
Demonstrates understanding of the effect of medicines on pregnant patients, including toxicity and potential risks to the foetus.	S	Adv II

19 Breastfeeding		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the role of multimodality treatment of cancers (surgery, radiotherapy, systemic therapies) in breast feeding patients and the potential risks to the baby.	S	Adv II
Demonstrates understanding of the effect of medicines on breastfeeding patients, including toxicity and potential risks to the baby.	S	Adv II
Demonstrates understanding of the excretion of systemic therapies in breast milk.	S	Adv II

20 Older People		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the role of multimodality treatment of cancers (surgery, radiotherapy, systemic therapies) for older people.	S	Adv I
Demonstrate knowledge/understanding of the impact of aging on the incidence of cancer.	S	Adv I
Demonstrate knowledge/understanding of the impact of co-morbidities on cancer treatment in older people.	S	Adv I

21 HIV		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the role of multimodality treatment of cancers in HIV patients (surgery, radiotherapy, systemic therapies).	S	Adv I
Demonstrate knowledge/understanding of the impact of HIV on the incidence of cancer.	S	Adv I
Demonstrate knowledge/understanding of the impact of co-morbidities on cancer treatment in HIV patients.	S	Adv I

22 Toxicology		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrates understanding of the possible toxic effects of drugs in cancer patients taking multiple medicines, especially for patients with suboptimal organ function associated with cancer.	G	Adv I
Demonstrates understanding of the importance of identifying and managing high risk drugs and long term medication in cancer patients to reduce risk of toxicity.	S	Adv I
Demonstrates utilisation of current information eg from National Patient Safety Agency and Medicines Healthcare products Regulatory Agency to reduce risk of medicines-related toxicity to cancer patients.	S	Adv I

23 Parenteral Therapy		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrates awareness of routes of administration of cancer drugs and the complications.	S	Adv I
Demonstrates awareness of national and local policies for intra-theccal chemotherapy.	G	Adv I
Demonstrate the use of speciality devices for drug administration, including infusion pumps.	G	Adv I
Demonstrate knowledge of the stability and compatibilities of drugs in infusions, syringe drivers, etc.	S	Adv I
Demonstrate awareness of the care of central venous access devices (CVAD).	S	Adv I

24 Paediatrics		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the role of multimodality treatment of cancers in paediatric patients (surgery, radiotherapy, systemic therapies).	S	Adv I
Demonstrate knowledge/understanding of the incidence of cancer in paediatric patients.	S	Adv I
Demonstrate knowledge/understanding of the impact of co-morbidities on cancer treatment in paediatric patients.	S	Adv I

25 Palliative and End of Life Care		
(NB – Refer to Palliative Care (Adults) Curriculum)	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate understanding and treatment of cancer-related pain.	G	Adv I
Demonstrates understanding of the role of syringe drivers in palliative care including compatibility of multiple drugs in syringe drivers.	S	Adv I
Demonstrates understanding of the basic principles of palliative care and management options for symptom control at end of life.	S	Adv II
Demonstrate knowledge of the Liverpool Care Pathway (LCP)/Gold Standards Framework (GSF).	S	Adv II
The care of the patient at the end of life.	G	Adv I

26 Clinical Trials		
Understanding of the role of the pharmacist in clinical trials. Including the role of the pharmacist in informing and supporting the patient.	S	Adv I
Demonstrate an understanding of clinical trials in cancer patients, including endpoints, ICH-GCP and the EU directive, trust policies and procedures, pharmacy documentation required, role of MDT in trials, phases of trials.	S	Adv I
Demonstrate knowledge of clinical trials open at local site.	S	Adv I
Demonstrate knowledge of how to set up clinical trials in local trust.	G	Adv II
Demonstrate knowledge of clinical trial design and interpretation.	G	Adv II
Demonstrate ability to interpret clinical trial data for local practice.	G	Adv II
To undertake Good Clinical Practice (GCP) training on a regular basis, dependent on organisational requirements.	S	Adv I

27 Other issues in Surgery		
	Specialist or Generalist	Advanced Stage I, Advanced Stage II or Mastery
Demonstrate knowledge/understanding of the epidemiology, risk factors and management of cancers of unknown origin.	S	Adv I
Demonstrate an understanding of national standards of practice, for example NICE, NCAG report, National Cancer Standards, Cancer Reform Strategy, NPSA alerts (see supporting references below). Affect of these standards on patient treatment and care.	S	Adv I
Demonstrate an understanding of cancer agenda, for example drug costs, public demand for new treatments, top ups, the role and contribution of NICE, the mixed economy of care, funding of new treatments, Cancer Drug Fund (CDF).	S	Adv I
Strategic overview of developments in cancer care e.g. peer review, the key worker, acute oncology services, chemotherapy closer to home.	S	Adv II
Demonstrate an understanding of the role of pharmacists in clinics and non-medical prescribing.	S	Adv I
Demonstrate an understanding of holistic assessment, patient centredness, survivorship and living with chronic disease, coping skills.	S	Adv I
Demonstrate an understanding of informed consent, information giving, and education.	S	Adv II
Understanding factors which influence compliance with treatment regimens.	S	Adv I
Understanding of and contribution to the multidisciplinary team (MDT), particularly with regard to advice and education. The importance in leading on issues in which pharmacists have specific expertise.	S	Adv II
Knowledge of the needs of Young Adults with cancer, e.g. developmental and social needs and local shared care arrangements.	S	Adv II
Knowledge of the side effects and their treatment of radiotherapy dependent on site and extent of treatment e.g. mucositis, diarrhoea, nausea and vomiting.	S	Adv II
Knowledge of the long term sequelae of radiotherapy e.g. osteoradionecrosis, fistulae formation, pulmonary fibrosis, cardiotoxicity, chronic bleeding, fatigue.	S	Adv II
The use of unsealed sources or radiation in the management of metastatic prostate and breast cancer e.g. strontium and samarium. Understanding radiation protection.	S	Adv II
Knowledge of the surgical treatment of cancers.	S	Adv II
Demonstrate awareness of indications and goals of cancer treatments in primary and recurrent malignancies, including neo-adjuvant, adjuvant, concomitant treatments.	S	Adv I
Demonstrate an understanding of psychological support of cancer patients including pharmacological and non-pharmacological interventions.	S	Adv II
Demonstrate an understanding and knowledge of public health education to prevent cancer, e.g. smoking cessation, weight loss programmes, sun protection.	S	Adv I
Understanding/knowledge of communications skills requirements for health care professionals working with cancer patients.	S	Adv II

Understanding/knowledge of patient education and the pharmacists' role.	S	Adv II
Demonstrate an understanding and knowledge of pharmacogenetics and its relevance to anti-cancer treatments.	S	Adv II
Demonstrate an understanding and knowledge of cancer vaccines and gene therapy treatments for cancer, including handling requirements, legislation, standards.	S	Adv II
Demonstrate an understanding and knowledge of therapeutic radio-pharmacy agents.	S	Adv II
Demonstrate an understanding and knowledge of BOPA guidance for pharmacists, e.g. dispensing oral chemotherapy, screening competency.	S	Adv I
Demonstrate knowledge of the relevance and impact of national cancer screening programmes e.g. breast, colorectal, prostate, cervical cancers.	S	Adv II
Demonstrate knowledge/understanding of the late effects of cancer treatment e.g. infertility, cardiotoxicity, hepatotoxicity, secondary cancers, etc.	S	Adv II
Demonstrate knowledge and understanding of medicines legislation, e.g. promotion, clinical trials, compassionate use.	S	Adv I
Demonstrate knowledge and understanding of drug safety issues, e.g. processes for monitoring, risk management.	G	Adv I
Demonstrate knowledge/understanding of data interpretation. To understand the relevance of specific cancer related end-points.	S	Adv II
Demonstrate knowledge/understanding of formulation issues with anti-cancer treatments e.g. crushing tablets, handling and stability of anti-cancer products.	G	Adv I







**ROYAL PHARMACEUTICAL SOCIETY  
FACULTY**

1 Lambeth High Street

London SE1 7JN

0845 257 2570

0207 7572 2737

[www.rpharms.com/faculty](http://www.rpharms.com/faculty)